<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04288193</url>
  </required_header>
  <id_info>
    <org_study_id>RPH-APDP-001</org_study_id>
    <nct_id>NCT04288193</nct_id>
  </id_info>
  <brief_title>Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the PACE Setting: A Pilot Study</brief_title>
  <official_title>Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the Program of All-inclusive Care for the Elderly (PACE) Setting: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tabula Rasa HealthCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tabula Rasa HealthCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to determine the feasibility of implementing an antipsychotic
      deprescribing initiative that is driven by pharmacists working collaboratively with the
      Program of All-inclusive Care for the Elderly (PACE) interdisciplinary team.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No individual antipsychotic has been approved by the U.S. Food and Drug Administration (FDA)
      for treating insomnia or behavioral and psychological symptoms of dementia (BPSD). Despite
      these medications being associated with significant harms, a considerable portion of older
      adults are prescribed antipsychotics for treatment of insomnia or BPSD. The aim of this study
      is to determine the feasibility of a pharmacist-driven antipsychotic deprescribing initiative
      in a community-based practice setting known as Program of All-inclusive Care for the Elderly
      (PACE). Our primary objective is to assess and describe the implementation process, including
      barriers and enablers to implementation. Our secondary objectives are to quantify and
      describe changes in antipsychotic prescribing following implementation; evaluate and report
      on antipsychotic re-initiations or changes in dosing; and evaluate and report on adverse drug
      withdrawal events (ADWEs) following antipsychotic deprescribing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Identify barriers and enablers to implementation of antipsychotic deprescribing initiative.</measure>
    <time_frame>Three months</time_frame>
    <description>Qualitative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implement changes in antipsychotic prescribing to patients in the PACE population.</measure>
    <time_frame>Three months</time_frame>
    <description>Quantitative and Qualitative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the number of antipsychotic re-initiations in the PACE population.</measure>
    <time_frame>Three months</time_frame>
    <description>Quantitative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure changes in antipsychotic dosing for the PACE population.</measure>
    <time_frame>Three months</time_frame>
    <description>Quantitative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the number of adverse drug withdrawal events (ADWEs) in the PACE population.</measure>
    <time_frame>Three months</time_frame>
    <description>Quantitative and Qualitative</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Behavioral and Psychiatric Symptoms of Dementia</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Trinity Health LIFE New Jersey PACE</arm_group_label>
    <description>Participants enrolled in Trinity Health LIFE New Jersey PACE facility who received an antipsychotic medication for the treatment of BPSD or insomnia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recommendation to Deprescribe</intervention_name>
    <description>Recommendation to Deprescribe</description>
    <arm_group_label>Trinity Health LIFE New Jersey PACE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Program of All-inclusive Care for the Elderly (PACE) is a Medicare-Medicaid program that
        provides comprehensive medical and supportive services to individuals &gt;55 years of age who
        are certified by their state as needing nursing home care but are able to live safely in
        the community through PACE, as an alternative to institutionalization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant enrolled in a PACE organization during the implementation time period;

          -  PACE organization contractually receiving pharmacy services from CareKinesis during
             the implementation time period; and,

          -  Participant's prescriber determines that the participant could potentially benefit
             from deprescribing the antipsychotic.

        Exclusion Criteria:

          -  A diagnosis of bipolar disorder, schizophrenia, schizo-affective disorder, acute
             delirium, Tourette's syndrome, tic disorders, autism, intellectual disability,
             developmental delay, obsessive-compulsive disorder, alcoholism, cocaine abuse,
             Parkinson's disease psychosis, or major depressive disorder for which the
             antipsychotic is specifically prescribed as adjunctive treatment;

          -  Participant's prescriber determines that the participant would likely not benefit or
             could be harmed from deprescribing the antipsychotic; and,

          -  Participant, or healthcare decision-maker on behalf of the participant (e.g.,
             caregiver) refuses to participate in the deprescribing initiative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique Michaud, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabula Rasa HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Furman, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabula Rasa HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriana Matos, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabula Rasa HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nishita Amin, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabula Rasa HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Briana Skalski, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabula Rasa HealthCare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sweilem Al Rihani, PhD, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tabula Rasa HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronique Michaud, PhD</last_name>
    <phone>4074549933</phone>
    <email>vmichaud@trhc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Dow, MS</last_name>
    <phone>4074549950</phone>
    <email>pdow@trhc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Trinity Health LIFE, New Jersey</name>
      <address>
        <city>Pennsauken</city>
        <state>New Jersey</state>
        <zip>08109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Patricia Pokrandt</last_name>
      <phone>856-675-3675</phone>
      <email>Patricia.Pokrandt@trinity-health.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna Marhsalick</last_name>
      <phone>(856) 675-3675</phone>
      <email>AMarshalick@mercyhealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008 Oct;56(10):1946-52. doi: 10.1111/j.1532-5415.2008.01916.x. Epub 2008 Sep 2.</citation>
    <PMID>18771457</PMID>
  </reference>
  <reference>
    <citation>Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008 Apr;33(5):957-70. Epub 2007 Jul 18. Review.</citation>
    <PMID>17637610</PMID>
  </reference>
  <reference>
    <citation>Feng Z, Hirdes JP, Smith TF, Finne-Soveri H, Chi I, Du Pasquier JN, Gilgen R, Ikegami N, Mor V. Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. Int J Geriatr Psychiatry. 2009 Oct;24(10):1110-8. doi: 10.1002/gps.2232.</citation>
    <PMID>19280680</PMID>
  </reference>
  <reference>
    <citation>Yan J. FDA extends black-box warning to all antipsychotics. Psychiatric News. 2008;43:1-27.</citation>
  </reference>
  <reference>
    <citation>US Government Accountability Office. Antipsychotic drug use: HHS has initiatives to reduce use among older adults in nursing homes, but should expand efforts to other settings. Washington, DC: US Government Accountability Office; 2015.</citation>
  </reference>
  <reference>
    <citation>U.S. Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. Silver Spring, MD: Center for Drug Evaluation and Research. 2008.</citation>
  </reference>
  <reference>
    <citation>Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int Psychogeriatr. 2011 Oct;23(8):1249-59. doi: 10.1017/S1041610211000755. Epub 2011 Jun 20.</citation>
    <PMID>21682938</PMID>
  </reference>
  <reference>
    <citation>U.S. Food and Drug Administration. Public health advisory:deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring, MD: Center for Drug Evaluation and Research. 2005.</citation>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>antipsychotic</keyword>
  <keyword>bpsd</keyword>
  <keyword>deprescribing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

